Similarly, the HER2CLIMB trial[8] showed that when tucatinib is combined with trastuzumab and capecitabine in patients with HER2+ metastatic BC, the most common adverse events include diarrhea (68%), nausea (42%), and vomiting (30%). This evidence concerns the gene ERBB2 and breast cancer.